HK152395A - Bone marrow suppressing agents - Google Patents

Bone marrow suppressing agents

Info

Publication number
HK152395A
HK152395A HK152395A HK152395A HK152395A HK 152395 A HK152395 A HK 152395A HK 152395 A HK152395 A HK 152395A HK 152395 A HK152395 A HK 152395A HK 152395 A HK152395 A HK 152395A
Authority
HK
Hong Kong
Prior art keywords
bone marrow
suppressing agents
marrow suppressing
suppressing
holmium
Prior art date
Application number
HK152395A
Other languages
English (en)
Inventor
Jaime Simon
Joseph R Garlich
David A Wilson
Kenneth Mcmillan
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of HK152395A publication Critical patent/HK152395A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK152395A 1988-12-19 1995-09-21 Bone marrow suppressing agents HK152395A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/284,875 US4882142A (en) 1988-12-19 1988-12-19 Bone marrow suppressing agents

Publications (1)

Publication Number Publication Date
HK152395A true HK152395A (en) 1995-09-29

Family

ID=23091850

Family Applications (1)

Application Number Title Priority Date Filing Date
HK152395A HK152395A (en) 1988-12-19 1995-09-21 Bone marrow suppressing agents

Country Status (17)

Country Link
US (1) US4882142A (da)
EP (1) EP0374501B1 (da)
JP (1) JP2795934B2 (da)
KR (1) KR0142907B1 (da)
AT (1) ATE92339T1 (da)
AU (1) AU625644B2 (da)
CA (1) CA2003326C (da)
DE (1) DE68908125T2 (da)
DK (1) DK175607B1 (da)
FI (1) FI895516A0 (da)
HK (1) HK152395A (da)
IE (1) IE69049B1 (da)
IL (1) IL92373A (da)
NZ (1) NZ231474A (da)
PH (1) PH26086A (da)
PT (1) PT92362B (da)
ZA (1) ZA898866B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US4976950A (en) * 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
US5133956A (en) * 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
US5320829A (en) * 1991-12-10 1994-06-14 The Dow Chemical Company Oral compositions for inhibiting plaque formation
ES2399480T3 (es) * 1997-11-10 2013-04-01 Memorial Sloan-Kettering Cancer Center Procedimiento de producción de formulaciones de trióxido de arsénico
CA2318471A1 (en) * 1998-01-06 1999-07-15 Alexander V. Kirichenko Nuclear scintigraphic assessment of mucosal function
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6794371B1 (en) * 1999-10-18 2004-09-21 The Dow Chemical Company Aminoalkylenephosphonates for treatment of bone disorders
US6565828B2 (en) * 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
US6776977B2 (en) * 2001-01-09 2004-08-17 Bristol-Myers Squibb Pharma Company Polypodal chelants for metallopharmaceuticals
US20030215391A1 (en) * 2001-07-19 2003-11-20 Carlos Rabito Fluorescent agents for real-time measurement of organ function
EP1458416A1 (en) 2001-12-13 2004-09-22 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US20030228256A1 (en) * 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
AU2002368450A1 (en) * 2002-12-10 2004-06-30 University Of Miami Radioablation of hemolymphopoietic cell populations
US20090252675A1 (en) * 2006-03-29 2009-10-08 Frank R Keith Radionuclide Therapy for Urinary Bladder Cancer
PL3054996T3 (pl) * 2013-10-07 2023-09-18 Igl Pharma, Inc. Sposób wytwarzania wysoce czystych środków do leczenia kości
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3302496B1 (en) * 2015-05-25 2021-01-06 IGL Pharma, Inc. Dotmp kit formulations for radioisotopes
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508625A (en) * 1982-10-18 1985-04-02 Graham Marshall D Magnetic separation using chelated magnetic ions
DE164843T1 (de) * 1984-06-04 1989-12-07 The Dow Chemical Co., Midland, Mich. Organische aminphosphonsaeurekomplexe fuer die behandlung von verkalkenden tumoren.
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents

Also Published As

Publication number Publication date
PT92362A (pt) 1990-06-29
FI895516A0 (fi) 1989-11-20
DE68908125D1 (de) 1993-09-09
DK582789A (da) 1990-06-20
KR0142907B1 (ko) 1998-07-15
EP0374501A1 (en) 1990-06-27
PT92362B (pt) 1995-09-12
IL92373A (en) 1995-08-31
EP0374501B1 (en) 1993-08-04
DE68908125T2 (de) 1994-03-03
US4882142A (en) 1989-11-21
AU625644B2 (en) 1992-07-16
JPH02237936A (ja) 1990-09-20
CA2003326A1 (en) 1990-06-19
ATE92339T1 (de) 1993-08-15
NZ231474A (en) 1992-06-25
DK582789D0 (da) 1989-11-20
ZA898866B (en) 1991-07-31
DK175607B1 (da) 2004-12-27
KR900009080A (ko) 1990-07-02
JP2795934B2 (ja) 1998-09-10
PH26086A (en) 1992-02-06
IE69049B1 (en) 1996-08-07
IE893714L (en) 1990-06-19
CA2003326C (en) 1999-01-19
AU4544089A (en) 1990-06-21

Similar Documents

Publication Publication Date Title
ZA898866B (en) Bone marrow suppressing agents
ZA886021B (en) Dental calculus inhibiting compositions
IE791203L (en) Radioactive scanning agents with hydroquinone as stabilizer
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
IL84944A (en) Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
ZA899734B (en) Macrocyclic aminophosphonic acid complexes,their preparation formulations and use
GB2219304B (en) Powdered carpet deodorizer compositions
IL86901A0 (en) 6,7-dihydropyrazolo-(1,5-a)(1,3,5)triazine-2-sulphonamide derivatives and herbicidal compositions containing the same
IL84844A0 (en) Pharmaceutical compositions comprising a certain carbazolone derivative or a salt thereof
GB8728675D0 (en) Compounds & compositions
IL98534A0 (en) The use of macrocyclic aminophosphonic acid complexes as imaging agents
OA09192A (en) "Stabilized sulfur dissolving compositions".
EP0201005A3 (en) 99mtc(iii)myocardial imaging agents which are non-reducable in vivo
KR880013576A (ko) 골수억제 조성물 및 이의 용도
GB2171920B (en) Mechanical horse for children's play
ZA882961B (en) Oral compositions comprising anti-calculus agents
IL86916A0 (en) Dental compositions containing chelating agents
CS804088A2 (en) Agent for plants' anthers sterilization
CS804388A2 (en) Agent for plants' anthers sterilization
CS804488A2 (en) Agent for plants' anthers sterilization
EP0301352A3 (en) Olefinic diphosphonic acids, process for their preparation and their use as threshold agents, as well as complexant compositions containing olefinic diphosphonic acids
ZA887306B (en) 1(2h)-phthalazinones as cytoprotective agents
IL113068A0 (en) Ligand-hapten conjugates of 1,4,7,10-tetraaza cyclododecane-n, n',n",n"'-tetraacetic acid
CS218888A1 (en) Adjusting intermediate insertion piece for planning heads' boring bars
IE883470L (en) Compositions for inhibiting dental plaque containing a¹polysaccharide

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20031121

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)